Stock FWBI FIRST WAVE BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. First Wave BioPharma, Inc.

Equities

FWBI

US33749P4081

Delayed Nasdaq
Other stock markets
 09:38:45 29/04/2024 pm IST 		5-day change 1st Jan Change
2.82 USD +2.92% Intraday chart for First Wave BioPharma, Inc. -3.09% -32.86%
29/03 First Wave BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
14/03 Sector Update: Health Care Stocks Retreating Late Afternoon MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Downgrades First Wave BioPharma to Neutral From Buy
MT
May CPI Inflation Slows in Line With Analysts' Expectations, Driving Narrow Premarket Gains for US Equity Futures
MT
HC Wainwright Adjusts First Wave BioPharma Price Target to $10 From $14, Maintains Buy Rating
MT
HC Wainwright Adjusts First Wave BioPharma Price Target to $14 From $18, Maintains Buy Rating
MT
HC Wainwright Reiterates First Wave BioPharma at Buy With $18 Price Target
MT
HC Wainwright Adjusts First Wave BioPharma's Price Target to $4 From $8, Keeps Buy Rating
MT
Roth Capital Adjusts First Wave BioPharma's Price Target to $9 from $20, Keeps Buy Rating
MT
Maxim Downgrades First Wave BioPharma to Hold From Buy
MT
AZURRX BIOPHARMA : Roth Capital Adjusts Price Target on AzurRx BioPharma to $5 From $7, Maintains Buy Rating
MT
AZURRX BIOPHARMA : HC Wainwright Adjusts Price Target on AzurRx BioPharma to $2.50 From $3.50, Maintains Buy Rating
MT
AZURRX BIOPHARMA : HC Wainwright Adjusts Price Target on AzurRx BioPharma to $3.50 From $2, Reiterates Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FWBI Stock
  4. News First Wave BioPharma, Inc.
  5. Analyst Reco.